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A potent non-peptide ET receptor antngonisl, myriceron caffeoyl ester (50-235), was isolated from the bayberry, ,44yrica ccr~$m~. This compound 
selectively antagonized specific binding of [“‘IlET-I, but not of [lz51]ET-3, to rnt cardiac membranes, ET-L-indud increase in the intracellular 
free calcium concentration i  Swiss 3T3 fibroblasts. and ET-l-induced contraction of rat aortic strips. Thus, 50-235 is the first non-peptide ET,, 
receptor antagonist. This compound cnn be useful for studying the physiological role of cndothclin and exploring its role in various diseases. 
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I. INTRODUCTION 
Endothelin (ET) is a peptide filmily consisting of 
three peptides (ET-l, ET-2 and ET-3) which were dis- 
covered by Yanagisawa et al. [I-3]. They found ET to 
be one of the most potent vasoconstrictors known of 
porcine coronary artery strips. The existence of the re- 
ceptor for ET in most tissues [4,5] suggests that ET 
contributes to many regulatory functions in the body. 
Although ET has been demonstrated to possess a spec- 
trum of pharmacological ctivities much wider than in- 
itially inferred [6] the physiological and pathological 
roles have been unclear because of the lack of specific 
antagonists. Recently, Ihara et al. [7] isolated a compet- 
itive peptide ET antagonist, cyclo(-D-Glu-L-Ala-allo+ 
Iie-L-Leu-o-Trp-) (BE-18257B), from the fermentation 
products of Streptmyces thaklnsis, and produced its 
potent synthetic analogs [S]. We have been searching for 
ET receptor antagonist activities in plant extracts, be- 
cause plants have been a good source for medicines, 
most of which interact with the corresponding specific 
receptors for neurotransmitters or neuropeptides in 
mammals. Here we report on a novel non-peptide ET, 
receptor antagonist, myriceron caffeoyl ester @O-235), 
which was discovered in bayberry, Myrica cer@mx 
2. MATERIALS AND METHODS 
2.1. Marerlals 
50235 WQS purified from the methanol extract of branches of Myr- 
icn ccrfi~‘u, as described elsewhere (Sakurai et al., in preparation). 
Carrespottdetm address: M. Fujimoto, Shionogi Research Labora- 
tories, Shionogi & Co., 5-12-4 Sagisu Fukushima-ku, Osaka 553, 
Japan. 
[“sI]ET-l and [‘?‘I]ET-3 were obtained from New England Nuclear. 
ET-l, ET-?.. ET-3, neuropcptide Y, bradykinin, angiotensin II, 
leupeptin and pepstatin A were obtained from the Peptide institute 
(Osaka, Japan). Fura-ZAM was obtained from Dojin (Kumamoto. 
Janan). Phcnvlmethvlsulfonvl fluoride (PMSF). aovbean trvosin in- 
h&to; and dacitracjn were-obtained f&m Sig& 6hem&l-&. (St. 
Louis, MO). and aprotinin from Boehringer (Mannhcim, Germany). 
2.2. Ccfi clrlrtrre 
Swiss 3T3 fibrublast cells were obtained from the American Type 
Culture Collection through Dainippon Seiyaku (Osaka, Japan), and 
cultured in Dulbecco’s modified Eae.le’s medium CNissui. Tokvo. 
Japan) supplemented with IO% fetal-calf serum (G&co), 50 rimi 
streptomycin, and 50 U/ml penicillin G (Gibco) in a 5% COcj95% air 
incubator at 37OC. 
2.3, Binding srudics 
The ventricles from rat hearts were minced with scissors and ho- 
mogenized in 7 ~01s. of ice-cold 20 mM NaHCO, containing 0. I mM 
PMSF (pM 7.4) with a Polytron homogenizer (Bringmann Instru- 
mcnts Inc., Westberg, NY). The homogenates were centrifuged at 
1,000 xg for 10 min. and then the pellet was disexded. The supmn- 
tant was centrifuged al 30,000 x g for 30 min. The pellel was washed 
once and resuspended in Tris buffer (50 mM, pM 7.4 at 25°C) contain- 
ing 0.1 mM PMSF, and stored at -80°C until use. Binding studies 
were performed according to the method described by Gu et al. [9]. 
In brief, cardiac membranes (0.21 mg/ml as prouin) were incubated 
with 25 pM [‘z’I]ET-I or [lzlr]ET-3, unless otherwise stated, in a final 
assay volume of 0.1 ml, in borosilicatedglass tubes. containing 50 mM 
Tris%C!. 0.1 mM PMSF, IO~~ml aprotinin, lOpB/ml lcupeplin. IO 
@/ml pepstatin A, 250pgIml bachracin and IO~g/ml soybean trypsin 
inhibitor (pW 7.4). Binding was performed for 60 min at 37OC. The 
binding reaction was terminated by the addition of 2.5 ml of ice-cold 
50 mM Tris-HCI (pH 7.4), followed by rapid fihration through a 
Whatman GFC &as fiber filter @e-soaked in 1% polyethyleniminc) 
under reduced pressure. The filters were then quickly washed 4 more 
times with 2.5 ml of the buffer. Radioactivity retained on the filter was 
counted. Non-specific binding was defined in the pnxncc of lo-’ M 
ET-I. Specific binding is the difference between total and non-specific 
binding. 
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2.4. Measrcrenmt of cytoJolic frrc cafciwt concentrution (iC& j,) itr 
Swiss 3T3 jibrobktsr cells 
[Ca2+li was Ruorometrically measured using the Ca’+-sensitive Ruo- 
rcscent dye, fura-2. Cells were dispersed with 0.025% trypsin/l mM 
EDTA. Cell suspensions were washed once with lhe growth medium. 
Cells were counted and resuspended in HEPES (20 mM)-buffered 
Hanks’ solution (pH 7.4) to a final concentration of 1 x 10” cclWm1. 
The cell suspensions were incubated with 2 .uM fura-2-AM at 37°C 
for 30 min. The fura-2-loaded cells thus obtained were resuspended 
in 0.3 ml of HEPES (20 mM)-buffered Hanks’ solution at 1 x IO6 
cells/ml in a cuvette (50 x 7 mm diameter) and continuously stirred. 
Pcptides were supplied in 3~1 of phosphate-buffered saline containing 
0.16 bovine serum albumin. 50-235 in I yl dimcthylsulroxide was 
added I min before the addition of the peptides. Fluorescence meas- 
urements were made with a specrrafluorometer (CAF-100, Japan 
Spectroscopy Inc., Tokyo, Japan) as described previously [IO]. 
2.5. Vasocomtriction cxperirnrnrs 
The measurement of mechanical response was done as previously 
described [I I], In brief, the thoracic aorta was isolated from a male 
Wistar rat. Adhering fat and connective tissues were removed and 
transvcrsc strips (2 mm wide and 4-5 mm long) were prepared. The 
endothelium was removed by gently rubbing rhe interior surface of the 
aorta. The strips were suspended inan organ bath containing modified 
Locke-Ringer solution (pH 7.4). which was bubbled with 95% Q/S% 
CO1 at 37OC. The composition of the solution was as follows (mM): 
NaCl 120, KCI, 5.6. NaHCO, 25, CaCI? 2,2, M&I. 1.0 and glucose 
5,G. The resting tension was adjusted to 1.5 p and each strip was 
allowed to equilibrate for 90 min. during which time the solution was 
replaced every IO-15 min. Isometric ontmctions were recorded on a 
polygraph system (Nihon Kodcn RM-6000) with a force-displace- 
ment transducer (Nihon Koden TDdllT). 
The contraction induced by 30 mM KC1 was determined first, After 
the KC1 had been washed out, the strips were prc-incubated for 5 min 
with various concentrations of 50-235, and the11 were contracted with 
ET-I. The concentration-response curves for ET-I obtaimxl in the 
absence and presence of SO-235 were compared. Contractions induced 
by 30 mM KC1 were taken as 10046, and relative values to these 
contractions were obtained. 
3. RESULTS 
We screened the extracts from approximately 400 
kinds of plants for ET receptor ligands. The result of 
this effort was the discovery of myriceron caffeoyl ester 
(50-235, Fig. l), a potent inhibitor of [“51]ET-1 binding 
to rat cardiac membranes. It was isolated from the 
methanol extract of the bark of the bayberry Myrica 
cerifera. The structure was determined by X-ray crystal- 
lographic analysis and NMR spectroscopy (Sakurai et 
al., manuscript in preparation). Rat cardiac membranes 
had high affinity-binding sites, not only for [*251]ET-1 
(& = 312 3 pM and f?,,, = 106 1 11 fmoYmg protein), 
but also for [1251]ET-3 (& = 48 2 18 pM and B,,, = 25 
& 4 fmol/mg protein). As shown in Fig. 2A and B, ET-l 
was 60”times more potent than ET-3 in displacing 
[“?]ET-1 binding, whereas ET-1 and ET-3 were equi- 
potent in displacing [“51]ET-3 binding. These results 
indicate that the [‘251]ET-I and [‘2SI]ET-3 binding are 
the ETA-type and ET,-type, respectively, according to 
the nomenclature of Sakurai et al. [12]. 50-235 displaced 
[‘ZSI]ET-I binding with a Ki value of 78 f 18 nM, IJUt 
this compound at 10e6 M inhibited only 25% of [“QET- 
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Fig. 1. Structure of myriceron caffeoyl ester (50.235). 
3 binding (Fig. 2A and B). No action of 50-235 was 
noted on [‘25i]neuropcptide Y binding to porcine hip- 
pocampal membranes [131p nor on [l’SI]angiotensin II 
binding to porcine aortic smooth muscle membranes 
[14] (data not shown). Scatchard analysis revealed that 
the presence of lo-’ M 50-235 reduced the affinity of 
[“SI]ET-l binding from 36 to 100 pM, with no change 
on the maximal density of the binding sites (Fig. 2C). 
This apparent competitive type of inhibition indicates 
that 50-235 interacts with the ET-l receptor binding 
sites themselves. 
The antagonistic effect of 50-235 for the ET receptor 
was further evaluated in functional assays. Swiss 3T3 
fibroblasts respond to ET isopeptides, bradykinin and 
bombesin, with increasing [Ca”]+ 50-235 inhibited the 
ET-l-induced increase in [Caz’li but did not substan- 
tially affect the [Ca’+]i increase induced by bradykinin 
or bombesin at lo-‘ M (Fig. 3). Prolonging the pre- 
incubation time enhanced the inhibitory effect of 50-235 
on the ET-1 response (Fig. 3A). However, when the cells 
were washed twice in HEPES-buffered Hanks’ solution 
after a 30 min incubation with IO-’ M 50-235 the ability 
of ET-l to increase [Ca”*li was partially recovered (Fig. 
3B). Adding lo-’ M 50-235 simultaneously with ET-1 
increased the ECso value of ET-1 for increasing [CaZ’li 
(from 9 to 16 nM), as shown in Fig. 3C. The dissocia- 
tion constant (&) of 50-235 was 130 nM, which was 
similar to its Ki value for inhibiting [“SI]ET-l binding 
(78 nM), when calculated according to the equation 
[15]: 
(N/A) - 1 = B/K‘, 
where A’ and A are E&‘s of ET-1 in the presence and 
absence of 50-235, respectively, and B is the concentra- 
tion of 50-235 (lo-’ M). When the cells were challenged 
with 10m8 M ET-1 after a I-min pre-incubation with 
50-235 the I& value of SO-235 was 14 & 1 nM (Fig. 
3D). Furthermore, 50-235 inhibited the ET-l-induced 
[Ca2+]; increase in rat aortic smooth muscle A7r5 cells, 
rat C6 glioma, a rat neuronal cell line RT4-D, and a 
human fibroblast cell line CCDlBLU, but not in human 
Girardi heart cells (data not shown). 
ET-1 induced contraction of the transverse strip pre- 
pared from rat thoracic aorta in a concentration-de- 
pendent manner. 50-235 antagonized this ET-l-induced 
vasoconstriction at lo-’ and 10m6 M without reducing 
the maximum response (Fig. 4), whiie it had no direct 
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Fig. 2. (A,B) Inhibition by ET-l (o), ET-3 (0) and SO-235 (A} of specific [‘*“IlET-l- (A) and [lz51]ET-3 bindings(B) to rat cardiac membranes. (C) 
Scatchard analysis of specific f*2JI]ET-I binding in the absence (0) or presence of IO-’ M 50-235 (a). The figure shows Ihc results ofone representadve 
experiment which was repeated 3 limes, 
vsrsocontractile activity at 1O-6 M. The pAz value of 
50-235 analyzed by Schild plot was 6.65 f 0.13. SO-235 
had no effect on the contraction induced by KC1 and 
norepinephrine (data not shown). 
4. DISCUSSION 
The ET isopeptides exert diverse effects on the mam- 
malian body via different receptors [3,16,17]. Recently, 
complementary DNAs encoding two different types of 
ET receptors have been cloned and expressed [12,18]. 
They have been designated either as ETA, which dis- 
plays a high affinity for ET-I and ET-2, or as ETa, 
which shows the same affinity for all the ET isopeptides. 
50-235 appeared to be a selective antagonist for the ET, 
receptor, regardless of animal species, based on the fol- 
lowing findings: (i) SO-235 displaced [‘2SI]ET-l binding, 
but not [1251]ET-3 binding, to rat cardiac membranes 
with a Ki value of 78 nM. SO-235 had no effect on 
[“‘Ilneuropeptide Y and [llSI]angiotensin II binding at 
10e6 M; (ii) 50-235 inhibited the ET-induced [Ca’*]i n- 
crease in Swiss 3T3 Abroblasts, which express the ET,- 
receptor [19]. Furthermore, TO-235 at 10e6 M blocked 
the effect of ET isopeptides on [Ca*+]i in rat aortic 
smooth muscle A7r5 ceils, rat C6 glioma, rat neuronal 
cell line RTCD, and a human fibroblast cell line, 
CCD19LU, but not at all in hr?man Girardi heart cells, 
which express the ET,-receptor [203 (Mihara et al., 
manuscript in preparation); (iii) TO-235 antagonized 
vasoconstriction induced by ET-1 (Fig. 4) but had no 
effect on that induced by KC1 or norepinephrine. We 
are now studying the in viva effect of 50-235. 
ET-1 induces contraction of isolated arterial and ye- 
nous strips, including cerebral arteries and coronary 
arteries, from various mammalian species [6]. In in viva 
experiments intracisternal injections of ET-1 produced 
significant vasospasm in cats and dogs [2 1,221. Further- 
more, plasma and cardiac tissue concentrations of en- 
dogenous ET increased after the coronary ligation- 
reperfusion procedure in the infarction model of rats 
[23]. The development of a highly specific and sensitive 
radioimmunoassay for ET-1 revealed that plasma ET-l 
concentrations were significantly higher in patients with 
certain diseases, such as acute myocardial infarction, 
subarachnoid haemorrhagc, essential hypertension and 
end-stage renal failure [24-291. Although such findings 
suggested that ET-l is a candidate for critical mediators 
of these symptoms it is difficult to judge how much ET-l 
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Fig. 3, Effect of 50-235 on the agonist-induced increases in [Ca’+L in 
mouse Swiss 3T3 tibroblast cds. (A) Time-dependent inhibition by 
50-235 (lo-’ M) of the ET-I (IO-” M)-induced increases in[@‘Ii. (B) 
Revcrsibilhy of Ihe TO-235 cl%%. Cells were trealed with IO-’ M 
50.235 during the fura- londing (30 min) and then washed twice in 
HEPES-buffered Hanks’ solution. (C) Concentration-responsecurves 
for ET-l in the absence (c) or presence of lo-’ M TO-235 (m). 50-235 
was added simultaneously with ET-I. (D) Effects of 50-235 on the 
[Caz+ji increase induced by ET-I (O), bradykinin (@and bombesin (A) 
(IO-” M each). TO-235 was given 1 min before the addition of the 
peptides. The figure shows the results of one rcprcsentativc cxperimcnt 
which was repeated 3times. 
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Fig. 4. Concentmtion-contractile-response curves to ET-I under var- 
ious concentrations of 50-235 (G, none; A, lo-’ M; A, low6 M) in 
isolated rat thoracic aorta. 50-235 was given 5 min before the addition 
of ET-I. Contractions induced by 30 mM KCI, mcasurrd bcforc the 
start of the experiment, were taken as 100%. N = 4. 
contributes to the cause of such disorders, 50-235, as 
well as BE- 182S7B and its analogs, can be used to eluci- 
date the physiological and pathological roles of ET, and 
might be therapeutically useful in the treatment of dis- 
eases involving ET-l. 
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